Previous Close | 92.62 |
Open | 93.04 |
Bid | 93.16 x 0 |
Ask | 93.38 x 0 |
Day's Range | 93.04 - 93.85 |
52 Week Range | 79.21 - 94.52 |
Volume | |
Avg. Volume | 3,298,235 |
Market Cap | 190.513B |
Beta (5Y Monthly) | 0.47 |
PE Ratio (TTM) | 23.58 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 3.30 (3.53%) |
Ex-Dividend Date | Mar 07, 2024 |
1y Target Est | N/A |
Q1 2024 Legend Biotech Corp Earnings Call
It’s a stock market rule of thumb that big acquisitions tend to destroy shareholder value. Spin-offs, on the other hand, have the reassuring habit of being more likely to create it.
Alnylam (ALNY) reports better-than-expected first-quarter 2024 results as both earnings and revenues beat estimates, primarily driven by strong Amvuttra sales.